Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 3Recurrence 2Rectal Neoplasms 2Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Colonic Neoplasms 1Alopecia 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × Immunoconjugates × Clear all
NCT05011188 2025-08-27

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

University of California, San Francisco

Phase 1/2 Active not recruiting
44 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡